Boĭko, A N, Batysheva, T T, Matvievskaia, O V et al. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2006
This study looked at chronic fatigue (tiredness that doesn't go away) in young patients who had brain injuries or diseases like multiple sclerosis or other brain conditions. Researchers tested whether a medication called Fezam (made from piracetam and cinnarizin) could help reduce this fatigue. The medication did help reduce fatigue severity, particularly in MS patients, though some patients experienced mild side effects like sleep problems.
While ME/CFS differs from post-traumatic encephalopathy or MS-associated fatigue, understanding whether pharmacological interventions targeting neurological dysfunction can ameliorate chronic fatigue has translational relevance. This study suggests potential neurobiological subtypes of fatigue (depression-related vs. behavioral/regulatory dysfunction) that may inform mechanistic research in ME/CFS and guide treatment personalization.
This study does not establish that ME/CFS shares identical etiology with MS-related or post-encephalopathy fatigue; focal brain damage may operate through different pathways than post-viral or immunological mechanisms proposed in ME/CFS. The absence of a placebo or control arm means therapeutic benefit cannot be definitively separated from natural recovery or observer bias. Cross-sectional data cannot establish causality between depression, behavioral changes, and fatigue genesis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →